|
Sunday, 08/04/2013
|
Recent Development in Biomarker and Subgroup Identification for Tailored Therapeutics
Russell Wolfinger, SAS Institute Inc; Richard C. Zink, JMP Life Sciences, SAS Institute, Inc.
4:05 PM
|
Testing Pathway-Dose Interaction in Clinical Studies
Jia Kang, Merck
4:50 PM
|
Statistical Methods and General Principles of Exploratory Biomarker Analysis: Pathway to Personalized Medicine
Rui Tang, Amgen; Mike Hale, Amgen; Jing Huang, Amgen; Li Chen, Amgen Inc.
5:05 PM
|
|
Monday, 08/05/2013
|
Personalized Medicine and Statistical Learning
Michael R. Kosorok, The University of North Carolina-Chapel Hill
8:35 AM
|
Overview of Study Designs for Personalized Medicine
Lei Zhu, Boston University; Sandeep Menon, Pfizer Inc.; Siyan Xu, Boston University
9:05 AM
|
Personalized Medicine in Oncology: A Statistical Perspective
Cheng Rong, Amgen
9:20 AM
|
Evaluating Marker-Guided Treatment Selection Strategies
Junlong Li, Harvard University; Roland Matsouaka, Harvard University; Tianxi Cai, Harvard University
10:05 AM
|
Set-Valued Dynamic Treatment Regimes for Competing Outcomes
Eric Laber, NC State University; Daniel J. Lizotte, University of Waterloo; Bradley Ferguson, NC State University
10:35 AM
|
A Two-Stage Bayesian Design with Sample-Size Re-Estimation and Subgroup Analysis for Phase II Binary Response Trials
Wei Zhong, Genentech Inc.; Joseph S. Koopmeiners, University of Minnesota; Bradley P. Carlin, University of Minnesota
10:50 AM
|
Overview of Pharmacogenomics, Gene-Gene Interaction, System Genomics
Marylyn Ritchie, The Pennsylvania State University
2:45 PM
|
Pharmacogenomics: Statistical Challenges and Opportunities on the Journey to Personalized Medicine
Nicholas Tatonetti, Columbia University
3:05 PM
|
|
Tuesday, 08/06/2013
|
Introductory Overview Lecture 6: Personalized Medicine
Anastasios (Butch) Tsiatis, North Carolina State University
8:35 AM
|
Exploratory Subgroup Analysis: Subgroup Identification Approaches in Clinical Trials
Ilya Lipkovich; Alexei Dmitrienko, Quintiles
8:35 AM
|
Well-Studied Women Make History: Women's Health Research and the Future of Medicine (with commentary by Arlene Ash)
Karen Freund, Tufts University School of Medicine; Aimee R. Kroll-Desrosiers, University of Massachusetts Medical School, Dept. of Quantitative Health Sciences; Arlene S. Ash, University of Massachusetts Medical School
9:15 AM
|
Introductory Overview Lecture 6: Personalized Medicine
Stephen J. Ruberg, Eli Lilly & Company
9:25 AM
|
Recent Advances in Joint Models for Longitudinal and Time-to-Event Data
Dimitris Rizopoulos, Erasmus MC
12:31 PM
|
Identifying Subpopulations with Differential Risk Benefit Profiles
Tianxi Cai, Harvard University
3:20 PM
|
|
Wednesday, 08/07/2013
|
Random Effects Linear Models in Cross-Over Trials
Michael Kenward, University of London
8:35 AM
|
How to Maximize the Usefulness of Predictive Biomarker Data in Development of Personalized Medicines
Cong Chen, Merck and Company Inc
8:35 AM
|
Smooth Estimators of Optimal Dynamic Treatment Regimes
Kristin A. Linn, NC State University; Eric Laber, NC State University; Len Stefanski, North Carolina State University
8:35 AM
|
The Phenotypic Squeeze: What Can We Realistically Expect from Genetically Personalized Medicine and What Can Statisticians Do to Help Realize It?
Stephen Senn, CRP-Sante
8:55 AM
|
Statistical Method and Design: Identify the Subgroups Who Would Have Nontrivial Overall Benefit in the National Lung Screening Trial (NLST)
Ping Hu, Division of Cancer Prevention, National Cancer Institute
9:00 AM
|
Online Adjustment for Unwanted Variation in Molecular Assays
Terence Speed, The Walter & Eliza Hall Institute of Medical Research; Johann Gagnon-Bartsch , Department of Statistics, University of California at Berkeley; Laurent Jacob, Berkeley
9:15 AM
|
Role of Statistical Random-Effects Linear Models in Personalized Medicine
Francisco J. Diaz, University of Kansas Medical Center
9:35 AM
|
|
Copyright © American Statistical Association.